Dec 01, 2020 7:00am EST Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors
Nov 24, 2020 7:00am EST Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer
Nov 18, 2020 7:00am EST Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
Nov 05, 2020 7:00am EST Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and Developments
Sep 09, 2020 4:01pm EDT Sutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global Meeting
Sep 02, 2020 4:12pm EDT Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global Meeting
Aug 25, 2020 7:00am EDT Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors